title: Iron chelation as a potential therapy for neurodegenerative disease.
abstract: Neurodegenerative disorders include a variety of pathological conditions, which share similar critical metabolic processes such as protein aggregation and oxidative stress, both of which are associated with the involvement of metal ions. Chelation therapy could provide a valuable therapeutic approach to such disease states, since metals, particularly iron, are realistic pharmacological targets for the rational design of new therapeutic agents.
authors.affiliation: Division of Pharmaceutical Sciences, King's College London, London, UK. robert.hider@kcl.ac.uk
authors.forename: Robert C
authors.initials: RC
authors.lastname: Hider
authors.forename: Yongmin
authors.initials: Y
authors.lastname: Ma
authors.forename: Francisco
authors.initials: F
authors.lastname: Molina-Holgado
authors.forename: Alessandra
authors.initials: A
authors.lastname: Gaeta
authors.forename: Sourav
authors.initials: S
authors.lastname: Roy
mesh_terms: D000595:Amino Acid Sequence; D016229:Amyloid beta-Peptides / Q000737:chemistry; D000818:Animals; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008969:Molecular Sequence Data; D019636:Neurodegenerative Diseases / Q000188:drug therapy*; D015125:Oxyquinoline / Q000031:analogs & derivatives / Q000627:therapeutic use; D010446:Peptide Fragments / Q000737:chemistry; D011725:Pyridines / Q000627:therapeutic use
chemical_list: C121031:3-hydroxypyridin-4-one; D016229:Amyloid beta-Peptides; D007502:Iron Chelating Agents; D010446:Peptide Fragments; D011725:Pyridines; C075222:amyloid beta-protein (1-42); D015125:Oxyquinoline